CD8A and neoplasm: Consistent with a lack of immunogenicity, we observed no differences in tumor grade or burden at 16 weeks between KPM and KP mice treated continuously with CD4+ and CD8+ T cell-depleting antibodies (αCD4/8) (Extended Data Fig. 2k–p).